Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells

1471-2407-3-23 1471-2407 Research article Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells Konnikova Liza liza.konnikova@tufts.edu Kotecki Maciej maciej.kotecki@tufts.edu Kruger M Mathew matt@cochranlab.org Cochran H Brent cochran@cochranlab.org

Department of Physiology, Tufts University School of Medicine 136 Harrison Ave., Boston, Massachusetts, 02111, USA

BMC Cancer 1471-2407 2003 3 1 23 http://www.biomedcentral.com/1471-2407/3/23 10.1186/1471-2407-3-23 13678425 14 7 2003 17 9 2003 17 9 2003 2003 Konnikova et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background

Astrocytomas are the most common type of primary central nervous system tumors. They are frequently associated with genetic mutations that deregulate cell cycle and render these tumors resistant to apoptosis. STAT3,

signal

transducer and

activator of

transcription 3, participates in several human cancers by inducing cell proliferation and inhibiting apoptosis and is frequently activated in astrocytomas.

Methods

RNA interference was used to knockdown STAT3 expression in human astrocytes and astrocytoma cell lines. The effect of STAT3 knockdown on apoptosis, cell proliferation, and gene expression was then assessed by standard methods.

Results

We have found that STAT3 is constitutively activated in several human astrocytoma cell lines. Knockdown of STAT3 expression by siRNA induces morphologic and biochemical changes consistent with apoptosis in several astrocytoma cell lines, but not in primary human astrocytes. Moreover, STAT3 is required for the expression of the antiapoptotic genes survivin and Bcl-xL in the A172 glioblastoma cell line.

Conclusion

These results show that STAT3 is required for the survival of some astrocytomas. These studies suggest STAT3 siRNA could be a useful therapeutic agent for the treatment of astrocytomas.

Background

Astrocytomas are the most common type of primary tumors of the central nervous system. These tumors arise from either astrocytes or their progenitor cells 1 and represent the second leading cause of cancer related deaths in children and in young adults 12345. It is also the second fastest growing cause of cancer deaths among those over 65, and unlike lung cancer (first) and melanoma (third), no behavioral changes have been shown to reduce risk 6.

Astrocytomas are divided into four grades based on the malignancy of the tumor. Glioblastoma multiforme (GBM), grade IV, is the most common type with the worst prognosis 12345. Average post-operative survival after tumor resection is less than two years 12345. In young adults, grade IV astrocytomas usually progress from lower grade astrocytomas, while in older patients it frequently arises de novo 1234. Progressive astrocytomas are frequently associated with loss of function mutations in p53, Rb and Ink4a/p16 genes as well as amplifications of PDGFR, MDM2 and Cdk4 genes 578910111213. These mutations cause a deregulation of cell cycle and render these tumors resistant to apoptosis.

STATs,

signal

transducers and

activator of

transcription, are a family of transcription factors that transmit signals from cell surface receptors directly to the nucleus 14. Activation of all the STAT proteins is caused by phosphorylation of a single tyrosine residue that leads to dimerization via an intermolecular SH2 phosphotyrosine interaction 15161718. The dimerized STATs then translocate to the nucleus where they regulate gene expression by binding directly to high affinity DNA binding sites or by associating with other transcription factors 192021222324. They play a critical role in mediating cytokine and growth factor signaling involved in cell growth, differentiation and survival 25262728. Among the seven members of mammalian STAT family, STAT3 has been most strongly implicated in oncogenesis 29. STAT3 is ubiquitously expressed in mammalian cells and is activated by cytokines such as IL-6 family members as well as growth factors such as EGF and PDGF 30. Transient STAT3 activation is required for astrocytic differentiation 31. However, the role of STAT3 signaling in adult astrocytes is unclear.

Although spontaneous mutations in the STAT3 gene have not been associated with tumorigenesis, constitutively activated STAT3 is found in a wide variety of human tumors including multiple myelomas, breast, ovarian, prostate, and head and neck tumors 31323334353637. There is substantial evidence to implicate STAT3 activation in tumor progression. A number of studies have demonstrated that the transformation process induced by diverse oncogenic protein tyrosine kinases is dependent on STAT3 activation 373839. Inhibition of STAT3 signaling in a number of tumor cell lines with either small molecular inhibitors to block protein tyrosine kinases (PTKs) or with dominant negative/antisense STAT3 causes a decrease in cell viability and subsequent apoptosis 313440. Elevated STAT3 activity has been shown to render cells resistant to apoptosis by inducing anti-apoptotic genes such as Bcl2, Bcl-xL, and Mcl-137. Recently it has been shown that STAT3 is constitutively activated in astrocytomas 41. Here we show that knockdown of STAT3 expression by siRNA reduces levels of survivin and Bcl-xL expression and triggers apoptosis in astrocytoma cells.

Methods

Cell Lines and Culture Conditions

The human astrocytoma cell lines A172 and T98G were obtained from the American Type Culture Collection (Rockville, MD). The U251-MG cell line was graciously donated by Dr. George Perides (Tufts-NEMC). These cell lines were derived from grade IV astrocytomas – glioblastoma multiforme (GBM). Normal human astrocytes (NHA) were obtained from ScienCell (San Diego, CA). A172 and U251-MG cells were cultured in DMEM (ATCC, Rockville, MD) supplemented with 10% FCS. T98G was cultured in MEM (ATCC, Rockville, MD) supplemented with 10% FCS. Normal human astrocytes (NHA) were cultured in astrocyte medium (ScienCell, San Diego, MD).

STAT3 siRNA and siRNA transfections

We designed a double stranded siRNA oligonucleotide against STAT3 (5'-AAC AUC UGC CUA GAU CGG CUA dTdT-3'; 3'-dTdT GUA GAC GGA UCU AGC CGA U-5') and had it synthesized by Dharmacon Research, Inc (Lafayette, CO). Oligofectamine (Invitrogen, Carlsbad, CA) was used as the transfection reagent following manufacturer's directions using 200–600 nmol of siRNA per 10 cm dish. Cells were incubated for 24 hrs in Opti-MEM, at which point appropriate media for the cells supplemented with 30% FCS was added. The cells were then incubated for the amount of time indicated in the Figure Legends.

Immunoblotting

For Western blot analysis, cells were harvested and lysed with RIPA buffer (0.15 M NaCl, 1% NP40, 0.01 M desoxycholate, 0.1% SDS, 0.05 M Tris-HCl pH 8.0, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/ml each of aprotinin, pepstatin, and leupeptin). For STAT3 analysis, protein samples were electrophoresed on a 10% SDS-PAGE gels for 90 min. at 150 mV and transferred onto Immobilon membranes (Millipore, Bedford, MA) for 60 min at 100 mV in 10% methanol transfer buffer. For caspase-3 analysis the protein samples were separated on a 15% SDS-PAGE and transferred onto Immobilon membranes (Millipore, Bedford, MA) at 20 mV for 20 min and 80 mV for 2 hrs in 20% methanol transfer buffer. The membranes were then probed with each antibody as indicated. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). Anti-phospho-STAT3, anti-STAT3, anti-cleaved Caspase 3, anti-Bcl-xL and anti 42–44 MAP kinase were obtained from Cell Signaling (Beverly, MA). Anti-β-actin antibody was obtained from Sigma (St. Luis, MO).

Cell number assay

For cell proliferation assays, cells were incubated for 72 hrs in 96-well plates in quadruplicates. Viable cell number was determined by using MTS assay according to the manufacturer's instructions (CellTiter 96 AQ Non-radioactive proliferation kit, Son Luis, CA). The absorbance was measured at 490 nm with a 96-well plate reader.

FACS analysis

Cells were treated with siRNA as described above. After 96 hours, cells were isolated and stained with annexin V-EGFP (BD Biosciences Clontech, Palo Alto, CA). Cells were analyzed using FACS for fluorescence of annexin V positive cells. The fraction of annexin V positive cells in the siRNA treated population was determined using the super-enhanced DMax method of WinList software (Verity Software House, Topsham, ME).

Northern blot analysis

The A172 cell line was treated with STAT3 siRNA as described previously and RNA purified with TRIzol (Invitrogen, Carlsbad, CA). 10 μg of each RNA sample was loaded per well. After transferring onto a nylon membrane (Ambion, Austin, TX), it was probed with a survivin probe (Resgen) or p21 (gift of Sam Lee) labeled with ³²P. Hybridizations were performed with Express Hyb (BD Biosciences Clontech, Palo Alto, CA) and washed following the manufacturers protocol. Blots were exposed to Kodak MS film overnight and developed. Blots were then quantitated using a Molecular Dynamics phosphorimager.

Results

STAT3 is constitutively activated in astrocytoma cell lines

To determine whether STAT3 is expressed and constitutively activated in astrocytoma cell lines, we compared the level of STAT3 expression and tyrosine 705 STAT3 phosphorylation in normal human astrocytes (NHA) to that of three astrocytoma cell lines. Western Blot analysis with anti-STAT3 and anti-phosphotyrosine STAT3 antibodies revealed that STAT3 was overexpressed and overactivated in astrocytoma cells as compared to primary astrocytes (Figure 1). Reprobing the blot with anti-β-actin shows that variability in protein loading could not account for the observed differences in STAT3 expression.

Figure 1

STAT3 is expressed and active in GBM cell lines

STAT3 is expressed and active in GBM cell lines. The indicated cell lines were lysed in RIPA buffer after serum starvation for 24 hrs. Cell lysates were subjected to electrophoresis on an SDS PAGE gel and processed for Western blotting with anti-phospho-Tyr-STAT3, anti-STAT3, or anti-β-actin antibodies. NHA are primary human astrocytes. All other cell lines are grade IV astrocytoma (GBM).

STAT3 RNAi specifically reduces STAT3 expression in astrocytoma cell lines

Recent studies show that constitutive activation of STAT3 in variety of tumors directly contributes to their oncogenic potential by inducing proliferation and inhibiting apoptosis 4041. Thus, we sought to determine the effect of inhibiting STAT3 expression in astrocytoma cells.

To inhibit STAT3 expression in astrocytoma cells, we used the RNAi method adapted for mammalian cell culture by Elbashir et al 42. A number of 21 bp double stranded RNAs to human STAT3 were synthesized and tested for their ability to knockdown STAT3 expression in astrocytomas. Transfection of cells with one of these STAT3 siRNAs (Figure 2a) resulted in a highly significant and reproducible decrease in STAT3 expression levels as judged by Western Blotting (Figure 2b). The degree of knockdown achieved ranged from 75–95% depending upon the experiment and cell line used. STAT3 siRNA inhibited STAT3 expression in normal human astrocytes (NHA) as well as in astrocytoma cell lines (Figure 2b). Mock transfection with oligofectamine or with an siRNA to the green fluorescent protein (GFP) failed to reduce STAT3 expression. The effect of STAT3 siRNA was specific in that it failed to knock down expression of the unrelated proteins β-actin or Map Kinase. STAT3 knockdown by siRNA was found to be time dependent with the maximum effect achieved at 48–72 hrs of siRNA treatment (Figure 2c). This siRNA is human specific and does not efficiently knockdown expression of murine STAT3 (Data not shown).

Figure 2

Knockdown of STAT3 by siRNA in primary human astrocytes and astrocytoma cells

Knockdown of STAT3 by siRNA in primary human astrocytes and astrocytoma cells. A. Sequences of the synthetic siRNA duplex designed against human STAT3. B. The astrocytoma cell lines A172 and U251 and normal human astrocytes (NHA) cultured in 10 cm plates were transfected with 600 nmol STAT3 siRNA and after 72 hours processed for Western blotting with anti-STAT3 antibodies. The blots were subsequently stripped and reprobed with anti-β-actin or anti-Map Kinase antibodies as controls. C. A172 cells were transfected with 600 nmol STAT3 siRNA for the times indicated and processed for Western blotting with anti-STAT3 antibodies.

STAT3 RNAi induces morphology changes and decreases viability in astrocytoma cell lines

We noted that upon STAT3 siRNA treatment of some of the astrocytoma lines that cultures were less confluent and some cells became smaller and rounder than control oligofectamine treated cells (Figure 3a). Consistent with this, there were fewer cells in both A172 and U251-MG cultures treated with STAT3 siRNA as compared to control oligofectamine treated cultures 72 hours post transfection (Figure 3b). Transfecting A172 cells a second time with STAT3 siRNA 48 hours after the initial transfection resulted in an even greater reduction in cell number (>90% in A172 and 65% in U251) as compared to oligofectamine controls (data not shown). Viability of normal human astrocytes (NHA) was not significantly affected by STAT3 siRNAi treatment. Another astrocytoma cell line, T98G, was only slightly affected by reductions in STAT3 expression (Figure 3b). Thus, not all astrocytoma cell lines are equally responsive to STAT3 knockdown. The decrease in cell number caused by STAT3 siRNA treatment of astrocytoma cells implies that STAT3 participates in cell cycle progression, cell survival, or both. Staining A172 cells for DNA content after STAT3 siRNA treatment showed an increased proportion of cells in early S phase (data not shown). This could be due to an S phase cell cycle block or to preferential apoptosis of these cells in late S and G2/M.

Figure 3

STAT3 siRNA causes a decrease in cell number in glioblastoma cell lines

STAT3 siRNA causes a decrease in cell number in glioblastoma cell lines. A. A172 cells were transfected with a STAT3 siRNA (bottom panel) or a control siRNA (top panel). Cells were photographed 72 hours post transfection at 200× magnification. B. A172, U251, T98G, and NHA cells were transfected with STAT3 siRNA or mock transfected with oligofectamine (vehicle). Viable cell numbers were determined by MTS assay 72 hours after transfection. (*) indicates a P value <0.001.

STAT3 RNAi induces apoptosis in astrocytoma cells

The cell number decreases observed in conjunction with the morphological observations suggested that astrocytoma cells treated with STAT3 siRNA undergo apoptosis. To confirm that these cells undergo apoptosis in response to STAT3 knockdown, we examined three other indicators of apoptosis in the A172 cell line. First, cultures of astrocytoma cells were stained Hoechst 33258 dye and scored for apoptotic nuclei43. A significantly higher percentage of apoptotic nuclei were observed in STAT3 siRNA treated cells than in GFP siRNA or oligofectamine treated cells (Figure 4a). Consistent with this observation, Western blot analysis of astrocytoma cell extracts showed that there is increased cleavage of caspase 3 in STAT3 siRNA treated cells (Figure 4b). Finally, annexin V staining of control and STAT3 siRNA treated cells followed by fluorescence activated cell sorting analysis indicated a 77% increase in the fraction of annexin V positive cells, further confirming that these cells are undergoing apoptosis (Figure 4c)44. Together these data indicate that STAT3 regulates an anti-apoptotic program in astrocytomas and that inactivation of STAT3 leads to a rapid induction of apoptosis.

Figure 4

Induction of apoptosis in human astrocytomas by STAT3 RNAi

Induction of apoptosis in human astrocytomas by STAT3 RNAi. A. A172 cells were transfected with STAT3, GFP siRNAs, or mock transfected with oligofectamine (vehicle). After 72 hrs, cells were fixed in 4% paraformaldehyde and stained with 25 μg/ml Hoechst 33258 dye to visualize apoptotic nuclei. The percentage of apoptotic cells (small bright nucleus) was determined for each of the treatments by counting five visual fields and at least 100 cells. B. A172 cells were transfected with STAT3 siRNA or mock transfected with oligofectamine. Western blotting was performed 72 hrs post transfection. Blots were probed with α-STAT3, α-cleaved caspase 3 and α-β-actin antibodies. C. A172 cells were transfected with STAT3 siRNA (bottom panel) or mock transfected with oligofectamine (top panel). After 96 hours, cells were isolated and immunostained with EGFP coupled anti-annexin V antibody. Cells were sorted by FACS and annexin V positive cells counted. The region shaded in black (77%) corresponds the increase in annexin V positive cells relative to the mock transfected cells.

Knockdown of STAT3 expression down regulates survival genes

Recent data indicate that constitutive activation of STAT3 induces the expression of a number of anti-apoptotic genes including Bcl-xL, a member of the Bcl-2-family of anti-apoptotic genes 3245, and survivin, a member of the IAP,

inhibitors of

apoptotic

proteins family 46. Moreover, both of these genes are expressed in astrocytomas 4748. In order to determine whether these two genes might be involved in the STAT3 mediated apoptotic block in astrocytoma, Northern and Western blot analyses were performed to examine the expression levels of these two genes. Northern blot analysis showed that STAT3 siRNA reduced expression of survivin by 75% (Figure 5a). Western blot analysis showed that Bcl-xL protein levels were drastically reduced upon treatment with STAT3 siRNA. Thus, these data show that STAT3 regulates the expression of at least two distinct antiapoptotic genes in the A172 cell line.

Figure 5

STAT3 controls expression of survivin and Bcl-xL in the A172 human glioblastoma cell line

STAT3 controls expression of survivin and Bcl-xL in the A172 human glioblastoma cell line. A. A172 cells were transfected with STAT3 siRNA or mock transfected with oligofectamine. After 72 hours, RNA was isolated from the cells and then analyzed by northern blotting for survivin and p21 mRNA. B. A172 cells were transfected with STAT3 siRNA or mock transfected with oligofectamine. After 72 hrs, STAT3. β-actin, and Bcl-xL expression levels were analyzed by Western blotting.

Discussion

STAT3 is activated by a number of cytokines and growth factors and has diverse functions during embryogenesis and early development 25262728. Due to the transient nature of cytokine and growth factor signaling and the presence of proteins such as SOCS,

suppressor

cytokine

signaling, and PIAS,

protein

inhibitor of

activated

STAT, that inhibit of STAT3 signaling, STAT3 activation under normal physiological conditions is transient, lasting anywhere from several minutes to several hours 49. However, during tumorigenesis there is often constitutive activation of PTKs due to activating mutations or aberrant growth factor or cytokine signaling. Constitutive PTK signaling results in constitutive activation of STAT338. It is therefore not surprising that recent studies show that there is persistent activation of STAT3 in a number of human cancers including multiple myelomas, breast, ovarian and prostate carcinomas and head and neck tumors 323334353637.

The initial evidence that STAT3 signaling is critical to tumorigenesis came from the observation that activation of STAT3 is necessary for v-src induced transformation of NIH3T3 cells 3839. Subsequent studies have shown that STAT3 activation is crucial to cellular transformation induced by a number of viral oncogenes 37. Inhibition of STAT3 signaling with either dominant negative or antisense oligonucleotides against STAT3 suppresses the transformation process in some tumors 3450. Overexpression of a constitutively active mutant of STAT3 transforms 3T3 cells in culture 51. Finally, recent studies have shown that treatment of tumor cells with inhibitors of STAT signaling results in decreased cell viability and induces apoptosis 4041. Together these findings demonstrate that STAT3 signaling plays a critical role in both the transformation process and tumor progression in some types of cancer.

Ourselves and others have found STAT3 is constitutively activated in astrocytomas and astrocytoma cell lines 4152. This is consistent with the fact that human astrocytomas are often characterized by an amplification of either growth factor genes, such as PDGF, growth factor receptor genes, such as the EGF receptor, or cytokines such as IL-6 that can lead to constitutive activation of STAT3 5354. Not surprisingly, there was constitutive STAT3 activation in all astrocytoma cell lines tested. In contrast, NHA showed relatively little STAT3 expression and activation.

In order to determine the role of STAT3 in astrocytomas directly, we have used RNAi to specifically knock down the expression of STAT3 in several human astrocytomas. Treatment of astrocytoma cell lines with STAT3 siRNA resulted in morphologic and biochemical changes indicative of apoptosis. These results are consistent with results previously observed with dominant negative STAT3 in U251 cells 41. Although STAT3 siRNA decreased the amount of STAT3 present in NHA, it did not have a significant effect on their viability. This suggests that STAT3 may be an ideal target for cancer therapy since inhibition of STAT3 signaling induces tumor cell death, but does not kill normal astrocytes.

One mechanism by which STAT3 participates in tumorigenesis is by inhibiting apoptosis through the induction of anti-apoptotic genes. Biochemical studies have shown that astrocytoma cells express a number of death receptors but are resistant to death receptor mediated apoptosis 5556. Other studies have shown that survivin is overexpressed in some tumors and that overexpression of the gene is sufficient to block apoptosis in tumor cells 485758. We have found that both Bcl-xL, a member of the BCL2 family of proteins, and survivin are expressed in A172 cells (Figure 5a &5b). Treating A172 cells with STAT3 siRNA significantly reduces expression levels of both of these genes. STAT3 responsive elements are found in the promoter region of both of these genes, suggesting that they are directly regulated by STAT3 3246. Our findings that Bcl-xL is regulated by STAT3 in astrocytoma cell lines is consistent with previous data 41. We are the first to report that STAT3 also regulates survivin expression in astrocytoma. Taken together with our data that knockdown of STAT3 can induce apoptosis, these findings suggest that induction of Bcl-xL and survivin genes by constitutively activated STAT3 promotes survival of astrocytoma cells.

Not all the astrocytoma cell lines examined responded equally to STAT3 knockdown. This suggests that some astrocytomas are not dependent on STAT3 for survival. Further work is needed to determine whether this STAT3 independence has evolved from STAT3 dependent cells or more likely is a result of the specific types of oncogenic mutations in these tumors.

Data presented in this paper are consistent with the growing body of evidence suggesting STAT3 may be an important therapeutic target in tumors including astrocytoma. We are the first to report that an siRNA can induce apoptosis of astrocytoma cells. siRNAs are short oligonucleotides of 21–23 nucleotides in length that can be used in vitro to produce sequence specific gene silencing of mammalian cells 59. It has been shown that siRNAs can be used effectively in vivo to suppress gene expression in adult mice 6061. siRNAs can be directly introduced into the CNS to reduce endogenous gene expression 62. These results suggest that siRNA may become a useful clinical tool in the future. Since STAT3 signaling is important for the survival of a number of human tumors, STAT3 siRNA could become an effective therapeutic agent for STAT3 dependent tumors.

Conclusions

Knockdown of STAT3 expression by RNAi results in a reduction in expression of Bcl-xL and survivin in A172 cells and leads to induction of apoptosis in this and other astrocytoma cell lines.

Competing interests

None declared.

Authors' contributions

BHC and LK conceived and designed the experiments and wrote the manuscript. LK performed most of the experiments. MK performed and interpreted the FACS analysis. MMK helped with siRNA experiments, northern blots, and tissue culture. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by NIH grant GM51551 to BHC. LK was supported by Medical Scientist training grant NIH T32 GM08448.

Malignant glioma: genetics and biology of a grave matter Maher EA Furnari FB Bachoo RM Rowitch DH Louis DN Cavenee WK DePinho RA Genes Dev 2001 15 1311 1333 10.1101/gad.891601 11390353 Molecular pathogenesis of malignant gliomas Rasheed BK Wiltshire RN Bigner SH Bigner DD Curr Opin Oncol 1999 11 162 167 10.1097/00001622-199905000-00004 10328589 Biology and treatment of malignant glioma Prados MD Levin V Semin Oncol 2000 27 1 10 10866344 Glioblastoma multiforme: the terminator Holland EC Proc Natl Acad Sci U S A 2000 97 6242 6244 33993 10841526 10.1073/pnas.97.12.6242 The developmental biology of brain tumors Wechsler-Reya R Scott MP Annu Rev Neurosci 2001 24 385 428 10.1146/annurev.neuro.24.1.385 11283316 Neoplasms of the central nervous system In Cancer: Principles and practice of oncology Levin V A S. Leivei, P. H. Gutin Philadelphia, Lippincott-Raven V T DeVita S J Hellman SA Rosemberg 1997 2022 2082 Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Libermann TA Nusbaum HR Razon N Kris R Lax I Soreq H Whittle N Waterfield MD Ullrich A Schlessinger J Nature 1985 313 144 147 2981413 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Li J Yen C Liaw D Podsypanina K Bose S Wang SI Puc J Miliaresis C Rodgers L McCombie R Bigner SH Giovanella BC Ittmann M Tycko B Hibshoosh H Wigler MH Parsons R Science 1997 275 1943 1947 10.1126/science.275.5308.1943 9072974 Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Steck PA Pershouse MA Jasser SA Yung WK Lin H Ligon AH Langford LA Baumgard ML Hattier T Davis T Frye C Hu R Swedlund B Teng DH Tavtigian SV Nat Genet 1997 15 356 362 9090379 The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth Ivanchuk SM Mondal S Dirks PB Rutka JT J Neurooncol 2001 51 219 229 10.1023/A:1010632309113 11407594 Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities Ichimura K Bolin MB Goike HM Schmidt EE Moshref A Collins VP Cancer Res 2000 60 417 424 10667596 Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets Reifenberger G Ichimura K Reifenberger J Elkahloun AG Meltzer PS Collins VP Cancer Res 1996 56 5141 5145 8912848 CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas Schmidt EE Ichimura K Reifenberger G Collins VP Cancer Res 1994 54 6321 6324 7987821 STATs: Signal transducers and activators of transcription (review) Ihle JN Cell 1996 84 331 334 8608586 Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein Shuai K Schindler C Prezioso VR Darnell J. E., Jr. Science 1992 258 1808 1812 1281555 Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor Schindler C Shuai K Prezioso VR Darnell J. E., Jr. Science 1992 257 809 813 1496401 A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma Shuai K Stark GR Kerr IM Darnell J. E., Jr. Science 1993 261 1744 1746 7690989 Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions Shuai K Horvath CM Huang LH Qureshi SA Cowburn D Darnell J. E., Jr. Cell 1994 76 821 828 7510216 Inducible binding of a factor to the c-fos regulatory region Hayes TE Kitchen AM Cochran BH Proc Natl Acad Sci U S A 1987 84 1272 1276 3029776 Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha Schindler C Fu XY Improta T Aebersold R Darnell J. E., Jr. Proc Natl Acad Sci U S A 1992 89 7836 7839 49806 1502203 The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter Wagner BJ Hayes TE Hoban CJ Cochran BH Embo J 1990 9 4477 4484 2176154 Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins Veals SA Schindler C Leonard D Fu XY Aebersold R Darnell J. E., Jr. Levy DE Mol Cell Biol 1992 12 3315 3324 1630447 Functional interactions between Stat5 and the glucocorticoid receptor Stocklin E Wissler M Gouilleux F Groner B Nature 1996 383 726 728 10.1038/383726a0 8878484 DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites Ehret GB Reichenbach P Schindler U Horvath CM Fritz S Nabholz M Bucher P J Biol Chem 2001 276 6675 6688 10.1074/jbc.M001748200 11053426 STAT family of transcription factors in cytokine-mediated biological responses Takeda K Akira S Cytokine Growth Factor Rev 2000 11 199 207 10.1016/S1359-6101(00)00005-8 10817963 Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Hirano T Ishihara K Hibi M Oncogene 2000 19 2548 2556 10.1038/sj.onc.1203551 10851053 Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway Heinrich PC Behrmann I Muller-Newen G Schaper F Graeve L Biochem J 1998 334 ( Pt 2) 297 314 STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells Matsuda T Nakamura T Nakao K Arai T Katsuki M Heike T Yokota T Embo J 1999 18 4261 4269 10.1093/emboj/18.15.4261 10428964 Stat proteins and oncogenesis Bromberg J J Clin Invest 2002 109 1139 1142 150969 11994401 10.1172/JCI200215617 Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Zhong Z Wen Z Darnell J. E., Jr. Science 1994 264 95 98 8140422 Multiple routes to astrocytic differentiation in the CNS Rajan P McKay RD J Neurosci 1998 18 3620 3629 9570793 Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Catlett-Falcone R Landowski TH Oshiro MM Turkson J Levitzki A Savino R Ciliberto G Moscinski L Fernandez-Luna JL Nunez G Dalton WS Jove R Immunity 1999 10 105 115 10023775 STATs in oncogenesis Bowman T Garcia R Turkson J Jove R Oncogene 2000 19 2474 2488 10.1038/sj.onc.1203527 10851046 Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo Grandis JR Drenning SD Zeng Q Watkins SC Melhem MF Endo S Johnson DE Huang L He Y Kim JD Proc Natl Acad Sci U S A 2000 97 4227 4232 18206 10760290 10.1073/pnas.97.8.4227 Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6 Schuringa JJ Wierenga AT Kruijer W Vellenga E Blood 2000 95 3765 3770 10845908 Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells Badache A Hynes NE Cancer Res 2001 61 383 391 11196191 Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention Buettner R Mora LB Jove R Clin Cancer Res 2002 8 945 954 11948098 Stat3 activation by Src induces specific gene regulation and is required for cell transformation Turkson J Bowman T Garcia R Caldenhoven E De Groot RP Jove R Mol Cell Biol 1998 18 2545 2552 110634 9566874 Stat3 activation is required for cellular transformation by v-src Bromberg JF Horvath CM Besser D Lathem WW Darnell J. E., Jr. Mol Cell Biol 1998 18 2553 2558 110635 9566875 Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells Mora LB Buettner R Seigne J Diaz J Ahmad N Garcia R Bowman T Falcone R Fairclough R Cantor A Muro-Cacho C Livingston S Karras J Pow-Sang J Jove R Cancer Res 2002 62 6659 6666 12438264 Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells Rahaman SO Harbor PC Chernova O Barnett GH Vogelbaum MA Haque SJ Oncogene 2002 21 8404 8413 10.1038/sj.onc.1206047 12466961 Duplex of 21-nucleotide RNAs mediate RNA interfeerence in cultured mammalian cells Elbashir SM Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T Nature 2001 411 494 498 10.1038/35078107 11373684 Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations Elstein KH Zucker RM Exp Cell Res 1994 211 322 331 10.1006/excr.1994.1094 7511539 Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models Chan A Reiter R Wiese S Fertig G Gold R Histochem Cell Biol 1998 110 553 558 10.1007/s004180050317 9860253 STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells Zushi S Shinomura Y Kiyohara T Miyazaki Y Kondo S Sugimachi M Higashimoto Y Kanayama S Matsuzawa Y Int J Cancer 1998 78 326 330 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4 9766567 Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma Aoki Y Feldman GM Tosato G Blood 2003 101 1535 1542 10.1182/blood-2002-07-2130 12393476 Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal Martin S Toquet C Oliver L Cartron PF Perrin P Meflah K Cuillere P Vallette FM J Neurooncol 2001 52 129 139 10.1023/A:1010689121904 11508812 Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels Kleinschmidt-DeMasters BK Heinz D McCarthy PJ Bobak JB Lillehei KO Shroyer AL Shroyer KR Arch Pathol Lab Med 2003 127 826 833 12823036 STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration Li W Liang X Kellendonk C Poli V Taub R J Biol Chem 2002 277 28411 28417 10.1074/jbc.M202807200 12032149 Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo Niu G Heller R Catlett-Falcone R Coppola D Jaroszeski M Dalton W Jove R Yu H Cancer Res 1999 59 5059 5063 10537273 Stat3 as an oncogene Bromberg JF Wrzeszczynska MH Devgan G Zhao Y Pestell RG Albanese C Darnell J. E., Jr. Cell 1999 98 295 303 10458605 Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors Cattaneo E Magrassi L De-Fraja C Conti L Di Gennaro I Butti G Govoni S Anticancer Res 1998 18 2381 2387 9703883 Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells Thomas CY Chouinard M Cox M Parsons S Stallings-Mann M Garcia R Jove R Wharen R Int J Cancer 2003 104 19 27 10.1002/ijc.10880 12532415 IL-6 gene amplification and expression in human glioblastomas Tchirkov A Rolhion C Bertrand S Dore JF Dubost JJ Verrelle P Br J Cancer 2001 85 518 522 10.1054/bjoc.2001.1942 11506489 Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction Riffkin CD Gray AZ Hawkins CJ Chow CW Ashley DM Neuro-oncol 2001 3 229 240 11584892 Human astrocytic brain tumors express AP02L/TRAIL Rieger J Ohgaki H Kleihues P Weller M Acta Neuropathol (Berl) 1999 97 1 4 10.1007/s004010050948 9930888 Expression of survivin in primary glioblastomas Das A Tan WL Teo J Smith DR J Cancer Res Clin Oncol 2002 128 302 306 10.1007/s00432-002-0343-4 12073047 Survivin: role in normal cells and in pathological conditions O'Driscoll L Linehan R Clynes M Curr Cancer Drug Targets 2003 3 131 152 12678716 Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Elbashir SM Harborth J Lendeckel W Yalcin A Weber K Tuschl T Nature 2001 411 494 498 10.1038/35078107 11373684 Efficient delivery of siRNA for inhibition of gene expression in postnatal mice Lewis DL Hagstrom JE Loomis AG Wolff JA Herweijer H Nat Genet 2002 32 107 108 10.1038/ng944 12145662 RNA interference in adult mice McCaffrey AP Meuse L Pham TT Conklin DS Hannon GJ Kay MA Nature 2002 418 38 39 10.1038/418038a 12097900 Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake Makimura H Mizuno TM Mastaitis JW Agami R Mobbs CV BMC Neurosci 2002 3 18 134599 12423556 10.1186/1471-2202-3-18

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/3/23/prepub